

Date: 27th May, 2023

BSE Ltd.
Corporate Service Department
1st Floor, P.J. Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza, 3rd Floor,
Plot No. C/1, 'G' Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

Scrip ID: KRSNAA
Scrip Code: 543328

Symbol: KRSNAA
Series: EQ

Dear Sir/Madam,

Subject: Audited Financial Results FY2022-23

Please find enclosed herewith Audited (Standalone and Consolidated) Financial Results of the Company for the quarter and year ended on 31st March, 2023 along with Audit Report thereon.

It is requested to take this intimation on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN:03600332



Independent Auditor's Report on Consolidated Audited Annual Financial Results of the Group pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Krsnaa Diagnostics Limited

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying statement of Consolidated annual financial results of Krsnaa Diagnostics Limited (hereinafter referred to as the 'Holding Company') and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended March 31, 2023 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditor on separate audited financial statements of the subsidiaries the aforesaid Statement:

(i) includes the annual financial results of Holding Company and the following entities

Sr. No	Name of the Entities	Relationship with the Holding Company
1	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (Sas Nagar) Private Limited	Wholly Owned Subsidiary
7	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary



(ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (“the Act”) read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditor(s) in terms of their reports referred to in “Other Matter(s)” paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors’ Responsibilities for the Consolidated Financial Results

This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company’s Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.



In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group and of or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and of are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to



the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

1. The Statement includes the audited Financial Results of Seven (7) subsidiaries) whose Financial Statements reflect Group's share of total assets of INR 48.99 million as at March 31, 2023, Group's share of total revenue of INR 393.40 million, Group's share of total net (loss) after tax of INR (14.27) million, and Group's share of total comprehensive (loss) of INR (14.27) million for the period from April 01, 2022 to March 31, 2023 and Group's net cash inflow of INR 4.59 million for the year ended as on date respectively, as considered in the Statement, which have been audited by the other auditor whose reports on financial statements of these entities have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.

Our opinion is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.



MSKA & Associates

Chartered Accountants

2. The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W



Anup Mundhra
Partner
Membership No.: 061083
UDIN: 23061083BGTDAU7721



Place: Pune
Date: May 27, 2023

Statement of Consolidated Financial Results for the quarter and year ended March 31, 2023

(INR Million, except earnings per share)


Sr.No.	Particulars	Quarter ended			Year ended	
		March 31, 2023	December 31, 2022	March 31, 2022	March 31, 2023	March 31, 2022
		(Refer Note 5)	(Unaudited)	(Refer Note 5)	(Audited)	(Audited)
1	Income					
	Revenue from operations	1,332.26	1,180.98	1,082.47	4,871.23	4,554.50
	Other income	59.26	45.43	41.04	193.79	149.11
	Total Income	1,391.52	1,226.41	1,123.51	5,065.02	4,703.61
2	Expenses					
	Cost of material consumed	256.91	191.89	127.03	741.79	602.96
	Employee benefits expense	211.08	188.81	151.17	745.64	541.53
	Finance costs	22.36	22.63	17.96	76.97	184.90
	Depreciation and amortization expense	145.96	139.05	104.45	537.82	413.87
	Fees to hospitals and others	159.95	164.46	248.30	812.07	1,079.92
	Other expenses	359.47	341.74	275.71	1,348.72	1,015.33
	Total Expenses	1,155.73	1,048.58	924.62	4,263.01	3,838.51
3	Profit before tax (1) - (2)	235.79	177.83	198.89	802.01	865.10
4	Tax expenses					
	Income Tax charge	21.08	33.93	51.88	149.31	175.26
	(Excess)/short provision of tax relating to earlier years	-	0.52	-	0.52	-
	Deferred tax charge/(credit)	25.53	6.96	(32.35)	31.07	5.94
	Total tax expenses	46.61	41.41	19.53	180.90	181.20
5	Profit / (loss) for the quarter/year (3) - (4)	189.18	136.42	179.36	621.11	683.90
6	Other comprehensive Income					
	Items that will not be reclassified subsequently to profit and loss					
	Re-measurement gains / (losses) on defined benefit plans	3.02	1.17	4.61	6.54	4.32
	Income tax effect	(0.76)	(0.30)	(1.16)	(1.65)	(1.09)
	Total other comprehensive Income/(loss) for the quarter/year	2.26	0.87	3.45	4.89	3.23
7	Total comprehensive income/(loss) for the quarter/year, net of tax (5+6)	191.44	137.29	182.81	626.00	687.13
	Profit for the quarter/year					
	Attributable to:					
	Equity Holders of the Holding Company	189.18	136.42	179.36	621.11	683.90
	Non Controlling Interests	-	-	-	-	-
		189.18	136.42	179.36	621.11	683.90
	Total other comprehensive Income/(loss) for the quarter/year					
	Attributable to:					
	Equity Holders of the Holding Company	2.26	0.87	3.45	4.89	3.23
	Non Controlling Interests	-	-	-	-	-
		2.26	0.87	3.45	4.89	3.23
	Total comprehensive income for the quarter/year					
	Attributable to:					
	Equity Holders of the Holding Company	191.44	137.29	182.81	626.00	687.13
	Non Controlling Interests	-	-	-	-	-
		191.44	137.29	182.81	626.00	687.13
8	Paid-up equity share capital (Face Value of Rs. 5/- each)	156.99	156.99	156.99	156.99	156.99
	Other equity				7,230.37	6687.10
	Earnings per share - After Split (Not annualised for quarters)					
	Basic (Rs.)	6.03	4.35	5.40	19.78	22.89
	Diluted (Rs.)	5.88	4.24	5.40	19.29	22.88

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited


Pallavi Bhatwara
Managing Director

DIN: 03600332

Place: Pune
Date: May 27, 2023



Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Notes to Audited Consolidated Financial Results:

1. The above financial results were reviewed by the Audit Committee and approved by the Board Of Directors of the holding company in their meeting held on May 27, 2023. The audit of financial results for the year ended March 31, 2023 has been completed by the Statutory Auditors of the holding company and they have issued an unmodified report on the aforesaid results.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence, no separate segment information has been furnished herewith.
4. The Income Tax Department had conducted a search under the powers conferred to them under section 132 of the Income Tax Act, 1961 at the premises of the holding company and at certain other locations in July 2022. The holding company had provided and will continue to provide all possible assistance to the officials and furnish all explanations, information and clarifications as currently required/requested by the Department. The Income Tax authorities have not yet concluded the assessment and there is no Income Tax claim/demand by the Tax Authorities in relation to this search. This does not have any impact on the results for the financial year ended March 31, 2023.
5. The numbers for quarter ended March 31, 2023 and March 31, 2022 are the balancing numbers between audited number in respect of full year ended March 31, 2023 and published year to date numbers of nine month ended December 31, 2022, and audited numbers of full year ended March 31, 2022 and published year to date numbers of nine month ended December 31, 2021 respectively.
6. The board of directors of the holding company have recommended the final dividend of Rs 2.75 per equity share of the face value of Rs 5 per equity share for the year ended March 31, 2023. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the holding company.
7. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Consolidated Balance Sheet as at March 31, 2023

(INR Million)

Particulars	As at March 31, 2023 (Audited)	As at March 31, 2022 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	4,678.47	3,833.79
Capital work-in-progress	254.80	282.57
Intangible assets	28.28	23.15
Financial assets		
Investments	2.91	2.91
Other financial assets	1,711.16	1,155.15
Deferred tax asset (net)	13.88	7.88
Other non-current assets	151.81	114.61
Total non-current assets	6,841.31	5,420.06
Current assets		
Inventories	250.74	91.70
Financial assets		
Trade receivables	730.97	578.73
Cash and cash equivalents	227.20	884.53
Bank balances other than cash and cash equivalent	860.76	1,534.28
Other financial assets	117.96	118.56
Other current assets	69.99	133.67
Total current assets	2,257.62	3,341.47
Total Assets	9,098.93	8,761.53
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	156.99	156.99
Other equity	7,230.37	6,687.10
Non controlling interest	-	-
Total equity	7,387.36	6,844.09
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	110.00	196.22
Lease Liabilities	132.84	134.52
Other financial liabilities	336.81	294.13
Employee benefit obligations	12.26	3.16
Deferred Tax Liabilities	127.65	77.95
Other non-current liabilities	0.07	1.25
Total non-current liabilities	719.63	707.23
Current liabilities		
Financial liabilities		
Borrowings	55.00	60.08
Lease Liabilities	26.97	19.10
Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	6.82	3.27
ii) Total outstanding dues of creditors other than micro enterprise and small enterprise	614.43	769.73
Other financial liabilities	244.32	234.82
Other current liabilities	22.89	103.40
Employee benefit obligations	21.51	19.81
Current liabilities	991.94	1,210.21
Total Liabilities	1,711.57	1,917.44
Total Equity and Liabilities	9,098.93	8,761.53

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Statement of Consolidated Cash Flows for the year ended March 31, 2023

Particulars	(INR Million)	
	Year Ended	
	March 31, 2023 (Audited)	March 31, 2022 (Audited)
A. Cash flow from operating activities		
Profit for the period	802.01	865.10
Adjustments for:		
Depreciation and amortization expenses	537.82	413.87
Finance cost	76.97	184.90
Interest income	(159.17)	(122.44)
Loss on Sale/Disposal of Assets	(1.76)	2.48
Provision for doubtful trade receivable balances	(7.20)	8.30
Effect of Financial Instruments measured at amortised cost	(5.33)	(7.49)
Employee stock option scheme compensation	6.73	12.42
Operating profit before working capital changes	1,250.07	1,357.14
Changes in working capital		
(Decrease)/increase in trade payables	(167.29)	(60.04)
(Decrease)/increase in employee payables	17.35	12.81
(Decrease)/increase in other current liabilities	3.23	1.15
(Decrease)/increase in other non current liabilities	(1.18)	(31.78)
(Decrease)/increase in other non current financial liabilities	277.74	(58.01)
(Decrease)/increase in other current financial liabilities	(250.44)	16.00
Decrease/(Increase) in inventories	(159.04)	(19.61)
Decrease/(Increase) in trade receivables	(144.31)	160.33
Decrease/(Increase) in other current financial assets	71.97	(75.55)
Decrease/(Increase) in non current financial assets	(18.62)	35.45
Decrease/(Increase) in other current assets	6.21	(9.35)
Decrease/(Increase) in other non current assets	8.62	21.99
Cash generated from operations	894.31	1,350.53
Income tax paid (Net of refunds)	(131.30)	(66.29)
Net cash flows generated from operating activities (A)	763.01	1,284.24
B. Cash flow from Investing activities		
Payment for property, plant and equipment and Intangible assets	(1,413.60)	(1,322.19)
Proceeds from sale of property, plant and equipment and Intangible assets	66.34	10.90
Investment in term deposits with banks (having original maturity of more than three months)	156.92	(1,264.56)
Investment in Debt Mutual Fund	-	(0.01)
Interest received	101.45	169.50
Net cash flow used in investing activities (B)	(1,088.89)	(2,406.36)
C. Cash flow from Financing activities		
Proceeds from issuance of equity share capital	-	4,000.00
Repayment of long term borrowings	(91.30)	(1,594.31)
Proceeds/(Repayment) of short term borrowings (net)	-	(299.41)
Payment of lease liabilities	(39.70)	(38.16)
Share issue expenses	(68.50)	(146.81)
Dividend payment to equity shareholders	(78.49)	-
Interest paid	(53.46)	(161.41)
Net cash flow generated from/(used) in financing activities (C)	(331.45)	1,759.90
Net Increase in cash and cash equivalents (A+B+C)	(657.33)	637.78
Cash and cash equivalents at the beginning of the year	884.53	246.75
Cash and cash equivalents at the end of the year	227.20	884.53
Cash and cash equivalents comprise:		
Balances with banks		
On current accounts	211.31	287.53
Debit balance in bank overdraft	5.30	56.10
Fixed deposits with maturity of less than 3 months	-	537.49
Cash on hand	10.59	3.41
Total cash and bank balances at end of the year	227.20	884.53

Place: Pune
Date: May 27, 2023

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332



Independent Auditor's Report on Standalone Audited Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.

To the Board of Directors of Krsnaa Diagnostics Limited

Report on the Audit of Standalone Financial Results

Opinion

We have audited the accompanying statement of standalone annual financial results of Krsnaa Diagnostics Limited (hereinafter referred to as 'the Company') for the year ended March 31, 2023 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

(i) is presented in accordance with the requirements of the Listing Regulations in this regard; and

(ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management and Board of Directors' Responsibilities for the Standalone Financial Results

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.



MSKA & Associates

Chartered Accountants

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



MSKA & Associates

Chartered Accountants

Other Matters

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matter.

For M S K A & Associates
Chartered Accountants
ICAI Firm Registration No.105047W

Anup Mundhra
Partner
Membership No. 061083
UDIN: 23061083BGTDA5457



Place: Pune
Date: May 27, 2023

Statement of Standalone Financial Results for the quarter and year ended March 31, 2023

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2023	December 31, 2022	March 31, 2022	March 31, 2023	March 31, 2022
		(Refer Note 5)	(Unaudited)	(Refer Note 5)	(Audited)	(Audited)
1	Income					
	Revenue from operations	1,158.59	1,157.36	1,078.44	4,640.83	4,548.90
	Other income	59.38	45.51	41.21	194.10	149.28
	Total Income	1,217.97	1,202.87	1,119.65	4,834.93	4,698.18
2	Expenses					
	Cost of material consumed	256.91	191.89	127.03	741.79	602.96
	Employee benefits expense	186.33	162.95	141.22	656.27	527.38
	Finance costs	22.34	22.58	18.31	76.83	184.89
	Depreciation and amortization expense	145.97	139.03	104.45	537.82	413.87
	Fees to hospitals and others	124.56	159.16	248.29	761.63	1,079.92
	Other expenses	339.83	305.57	259.76	1,238.68	993.16
	Total Expenses	1,075.94	981.18	899.06	4,013.02	3,802.18
3	Profit before tax (1) - (2)	142.03	221.69	220.59	821.91	896.00
4	Tax expenses					
	Income Tax charge	21.08	33.93	51.87	149.31	175.26
	(Excess)/Short provision of tax relating to earlier years	-	0.52	-	0.52	-
	Deferred tax charge/(credit)	2.86	18.59	(24.59)	36.99	13.71
	Total tax expenses	23.94	53.04	27.28	186.82	188.97
5	Profit/ (loss) for the quarter/year (3) - (4)	118.09	168.65	193.31	635.09	707.03
6	Other comprehensive income					
	Items that will not be reclassified subsequently to profit and loss					
	Re-measurement gains / (losses) on defined benefit plans	3.35	1.20	4.98	6.89	4.69
	Income tax effect	(0.83)	(0.30)	(1.25)	(1.73)	(1.18)
	Total other comprehensive income/(loss) for the quarter/year	2.52	0.90	3.73	5.16	3.51
7	Total comprehensive income/(loss) for the quarter/year, net of tax (5+6)	120.61	169.55	197.04	640.25	710.54
8	Paid-up equity share capital (Face Value of Rs. 5/ each)	156.99	156.99	156.99	156.99	156.99
	Other equity				7,268.02	6,710.51
	Earnings per share (Not annualised for quarters)					
	Basic (Rs.)	3.76	5.37	5.85	20.23	23.66
	Diluted (Rs.)	3.67	5.24	5.85	19.72	23.66

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Notes to Audited Standalone Financial Results:

1. The above financial results were reviewed by the Audit Committee and approved by the Board Of Directors in their meeting held on May 27, 2023. The audit of financial results for the year ended March 31, 2023 has been completed by the Statutory Auditors and they have issued an unmodified report on the aforesaid results.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
4. The Income Tax Department had conducted a search under the powers conferred to them under section 132 of the Income Tax Act, 1961 at the premises of the company and at certain other locations In July 2022. The company had provided and will continue to provide all possible assistance to the officials and furnish all explanations, information and clarifications as currently required/requested by the Department. The Income Tax authorities have not yet concluded the assessment and there is no Income Tax claim/demand by the Tax Authorities in relation to this search. This does not have any Impact on the results for the financial year ended March 31, 2023.
5. The numbers for quarter ended March 31, 2023 and March 31, 2022 are the balancing numbers between audited number in respect of full year ended March 31, 2023 and published year to date numbers of nine month ended December 31, 2022, and audited numbers of full year ended March 31, 2022 and published year to date numbers of nine month ended December 31, 2021 respectively.
6. The board of directors have recommended the final dividend of Rs 2.75 per equity share of the face value of Rs 5 per equity share for the year ended March 31, 2023. The payment of dividend is subject to approval of shareholders at the ensuing Annual General meeting of the company
7. Previous period figures have been regrouped/ rearranged wherever considered necessary.

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Krsnaa Diagnostics Limited
CIN:L74900PN2010PLC138068

Standalone Balance Sheet as at March 31, 2023

(INR Million)

Particulars	As at March 31, 2023 (Audited)	As at March 31, 2022 (Audited)
I. ASSETS		
Non-current assets		
Property, plant and equipment	4,678.47	3,833.79
Capital work-in-progress	254.80	282.57
Intangible assets	28.28	23.15
Financial assets		
Investments	3.61	3.61
Other financial assets	1,710.94	1,155.15
Other non-current assets	151.81	114.61
Total non-current assets	6,827.91	5,412.88
Current assets		
Inventories	250.74	91.70
Financial assets		
Trade receivables	745.45	593.07
Cash and cash equivalents	221.32	883.24
Bank balances other than cash and cash equivalent	860.76	1,534.28
Other financial assets	117.89	121.79
Other current assets	69.77	133.59
Total current assets	2,265.93	3,357.67
Total Assets	9,093.84	8,770.55
II. EQUITY AND LIABILITIES		
Equity		
Equity share capital	156.99	156.99
Other equity	7,268.02	6,710.51
Total equity	7,425.01	6,867.50
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	110.00	196.22
Lease Liabilities	132.84	134.52
Other financial liabilities	336.81	294.13
Employee benefit obligations	8.96	2.61
Deferred Tax Liabilities	127.65	77.94
Other non-current liabilities	0.07	1.25
Total non-current liabilities	716.33	706.67
Current liabilities		
Financial liabilities		
Borrowings	55.00	60.08
Lease Liabilities	26.97	19.10
Trade payables		
i) Total outstanding dues of micro enterprises and small enterprises	6.82	3.27
ii) Total outstanding dues of creditors other than micro enterprise and small enterprise	584.34	761.26
Other financial liabilities	233.53	230.42
Other current liabilities	24.65	102.47
Employee benefit obligations	21.19	19.78
Current liabilities	952.50	1,196.38
Total Liabilities	1,668.83	1,903.05
Total Equity and Liabilities	9,093.84	8,770.55

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Statement of Standalone Cash Flows for the year ended March 31, 2023

(INR Million)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
	(Audited)	(Audited)
A. Cash flow from operating activities		
Profit for the period	821.91	896.00
Adjustments for:		
Depreciation and amortization expenses	537.82	413.87
Finance cost	76.83	184.89
Interest income	(159.17)	(122.44)
(Gain)/ loss on sale of fixed assets	(1.76)	2.48
Provision for credit Impaired/(Reversal in provision for credit impairment)	(7.20)	8.30
Effect of Financial Instruments measured at amortised cost	(5.33)	(7.49)
Employee stock option scheme compensation	6.73	12.42
Operating profit before working capital changes	1,269.83	1,388.03
Changes in working capital		
(Decrease)/increase in trade payables	(188.91)	(68.51)
(Decrease)/increase in employee payables	14.66	12.60
(Decrease)/increase in other current liabilities	1.88	0.20
(Decrease)/increase in other non current liabilities	(1.18)	(31.78)
(Decrease)/increase in other current financial liabilities	20.92	11.58
(Decrease)/increase in other non current financial liabilities	(0.01)	(58.00)
Decrease/(Increase) in trade receivables	(140.43)	146.01
Decrease/(Increase) in Inventories	(159.04)	(19.61)
Decrease/(Increase) in other current financial assets	71.79	(75.30)
Decrease/(increase) in non current financial assets	(18.40)	35.45
Decrease/(Increase) in other current assets	6.40	(9.27)
Decrease/(increase) in other non current assets	8.62	21.99
Cash generated from operations	886.13	1,353.39
Income tax paid (Net of refunds)	(131.30)	(66.29)
Net cash flows generated from operating activities (A)	754.83	1,287.10
B. Cash flow from Investing activities		
Payment for purchase property, plant and equipment and intangible assets	(1,413.60)	(1,322.64)
Proceeds from sale of property, plant and equipment and intangible assets	66.34	10.90
(Investment in)/Redemption of term deposits with banks (having original maturity of more than three months)	156.92	(1,264.56)
Investment in Debt Mutual Fund	-	(0.01)
Repayment by/(Loan granted to) subsidiaries	3.48	(3.48)
Investment in Equity Instruments of subsidiaries	-	(0.70)
Interest received	101.45	169.51
Net cash flow used in investing activities (B)	(1,085.41)	(2,410.98)
C. Cash flow from Financing activities		
Proceeds from issuance of equity share capital	-	4,000.00
Repayment of long term borrowings	(91.30)	(1,594.31)
Proceeds/(Repayment) of short term borrowings (net)	-	(299.41)
Payment of lease liabilities	(39.69)	(37.66)
Share Issue expenses	(68.50)	(146.85)
Dividend payment to equity shareholders	(78.49)	-
Interest paid	(53.36)	(161.40)
Net cash flow generated/(used) in financing activities (C)	(331.34)	1,760.37
Net Increase in cash and cash equivalents (A+B+C)	(661.92)	636.49
Cash and cash equivalents at the beginning of the year	883.24	246.75
Cash and cash equivalents at the end of the year	221.32	883.24
Cash and cash equivalents comprise:		
Balances with banks		
On current accounts	209.46	286.56
Debit balance in bank overdraft	5.30	56.09
Fixed deposits with maturity of less than 3 months	-	537.49
Cash on hand	6.56	3.10
Total cash and bank balances at end of the year	221.32	883.24

For and on behalf of Board of Directors
Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director
DIN: 03600332

Place: Pune
Date: May 27, 2023



Date: 27th May, 2023

BSE Ltd.
Corporate Service Department
1st Floor, P.J. Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza, 3rd Floor,
Plot No. C/1, 'G' Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

Scrip ID: KRSNAA
Scrip Code: 543328

Symbol: KRSNAA
Series: EQ

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 [the SEBI (LODR) Regulations].

We, Pallavi Bhatevara, Managing Director and Pawan Daga, Chief Financial Officer of Krsnaa Diagnostics Limited, having its Registered Office at S. No. 243/A, Hissa No 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Pune - 411019, India, hereby declare that, the Statutory Auditors of the Company, MSKA & Associates (FRN:105047W) have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company (Consolidated & Standalone) for the quarter and year ended 31st March, 2023.

This declaration is given in compliance to Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015, as amended by the SEBI (LODR) (Amendment) Regulations, 2016, vide Notification No. SEBI/LAD-NRO/GN/2016-17 /001, dated 25th May, 2016 and Circular No. CIR/CFD/CMD/56/2016, dated 27th May, 2016.

Kindly take this declaration on record.

Thanking you,

For Krsnaa Diagnostics Limited



Pallavi Bhatevara
Managing Director



Pawan Daga
Chief Financial Officer